Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Risk adjusted net present value: What is the current valuation of Pfizer's PF-07264660?
PF-07264660 is a monoclonal antibody commercialized by Pfizer, with a leading Phase II program in Atopic Dermatitis (Atopic Eczema). According...
Data Insights
PF-07264660 by Pfizer for Atopic Dermatitis (Atopic Eczema): Likelihood of Approval
PF-07264660 is under clinical development by Pfizer and currently in Phase II for Atopic Dermatitis (Atopic Eczema). According to GlobalData,...